ClinConnect ClinConnect Logo
Search / Trial NCT04215848

As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period

Launched by HAT YAI MEDICAL EDUCATION CENTER · Dec 31, 2019

Trial Information

Current as of June 07, 2025

Completed

Keywords

Asthma Allergy

ClinConnect Summary

The study will measure the efficacy of as-needed low dose ICS/ LABA in well controlled asthmatic patient comparing with low dose ICS in step down circumstance.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patients who have been diagnosed as asthma at least 6 months.
  • 2. Patients who have well controlled asthma by ACT \> 23 and ACQ-7 \< 0.75 at least 12 weeks with using budesonide/formoterol (160/4.5 μg/d) twice daily
  • 3. Patient who not be taking oral bronchodilator such as montelukast, theophylline, doxophylline but accept for taking anti histamine and intranasal steroid.
  • 4. Patients who able to do spirometry without contraindication.
  • Exclusion Criteria:
  • 1. History of using systemic steroid previous 12 week and respiratory infection History of pulmonary tuberculosis with residual lung lesion by chest radiograph recent serious medical condition such as myocardial infarction, stroke, pneumonia etc.
  • 2. History smoking less than 10 pack-years or be smoking
  • 3. History of asthma exacabation previous 12 week

About Hat Yai Medical Education Center

Hat Yai Medical Education Center is a leading institution dedicated to advancing medical education, research, and clinical trials in southern Thailand. With a commitment to improving healthcare outcomes, the center collaborates with various healthcare professionals and organizations to conduct rigorous clinical research aimed at enhancing patient care and treatment methodologies. Its state-of-the-art facilities and interdisciplinary approach foster an environment conducive to innovation and excellence in medical research, ensuring adherence to the highest ethical and scientific standards.

Locations

Hat Yai, Songkhla, Thailand

Patients applied

0 patients applied

Trial Officials

Narongwit Nakwan, M.D.

Principal Investigator

HatYai Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials